Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07539311 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
A Phase 2 study, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07539311 is a Phase 2 study that is actively recruiting participants, run by Genmab. The registered enrollment target is 160 participants.
The verdict
NCT07539311, a Phase 2 study, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All participants will receive active drug; no one will be given placebo. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective. The duration of the study will be different for every participant, but an average study duration of 22 months is expected for participants. This will include a treatment period (expected to last an average of 12 months), plus data collection periods before and after treatment. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of an individual cycle is 21 days). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Interventions
- BIOLOGICAL Rina-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07539311
The ClinicalTrials.gov registry entry for NCT07539311 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rina-S is the first listed.
NCT07539311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07539311 about?
NCT07539311 is a clinical study titled "Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers". This Phase 2 study will be conducted in different countries around the world with up to about 160 participants. The purpose of this study is to evaluate how well Rina-S works against GI cancers. The medication in this study is Rina-S monotherapy (by itself; no other cancer treatments). All partici...
What is the current status of trial NCT07539311?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-05-11. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07539311?
The interventions under investigation include: Rina-S (BIOLOGICAL).
Who is sponsoring clinical trial NCT07539311?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.